Deloitte Focuses on 'Transformation, Not Transactions' as the Necessary
Trend at AdvaMed 2007
WASHINGTON, Oct. 2 /PRNewswire/ -- Deloitte & Touche USA LLP Life Sciences Industry Group Vice Chairman Terry Hisey will lead a discussion on the intricacies of convergence partnerships tomorrow at AdvaMed 2007.
Amidst increased competition, R&D stagnation, expanding consumer demand, and pressures to reduce health care costs, companies in all sectors of the life sciences industry are finding new opportunities for innovation, growth and differentiation through convergence. Convergent solutions -- combination products that integrate two or more core technologies (diagnostics, devices, and/or drugs) -- are resulting in more patient-centered, efficient diagnosis and treatment.
Although partnerships are common in the life sciences industry, partnering to create convergent solutions presents unique challenges. Life sciences companies must make several strategic decisions in choosing and managing the convergence pathway. During his panel discussion, Mr. Hisey will highlight various examples of convergence, identify the driving forces behind the convergence trend, and discuss the pathways to convergence in the marketplace today. He will also propose a framework for considering investment alternatives under different scenarios of technological uncertainty, as well as present strategies for choosing a specific convergence pathway, managing successful cross-sector partnerships and alliance networks, and addressing regulatory challenges.
"AdvaMed's C-level audience commands true industry leaders who can provide insight into capitalizing on trends as they are unfolding," said Kenneth Mendez, Senior Executive Vice President and Chief Administrative Officer of AdvaMed. "Convergence is an area that holds a high level of interest, as it may provide tremendous growth opportunity for the life sciences industry."
"Developing a co
|SOURCE Deloitte & Touche USA LLP|
Copyright©2007 PR Newswire.
All rights reserved